secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010303
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.
- Q4 2022 net loss $70.4M ($1.35/sh) vs Q4 2021 net loss $93.2M ($1.79/sh).
- R&D expenses $56.0M in Q4 2022, down from $75.6M; G&A $18.1M vs $17.5M.
- Topline data from 4 Phase 3 tarcocimab studies (DME, NPDR, wAMD) expected Q3 2023.
- KSI-501 Phase 1 in DME screening patients; commercial cGMP manufacturing started at Ursus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/0000950170-23-010303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/kod-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer